Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers

Next Previous
Trial Profile

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AFM 24 (Primary) ; Atezolizumab (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AFM24-102
  • Sponsors Affimed Therapeutics

Most Recent Events

  • 23 Apr 2025 According to an Affimed Therapeutics media release, company will present initial results from a phase 2a study data from this study in two poster presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30-June 3, 2025 in Chicago, Illinois.
  • 25 Mar 2025 According to an Affimed Therapeutics media release, company announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois.
  • 17 Dec 2024 Results(As of the November 14, 2024 data cut) presented in the Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top